Minireviews
Copyright ©The Author(s) 2021.
World J Clin Cases. Apr 16, 2021; 9(11): 2419-2432
Published online Apr 16, 2021. doi: 10.12998/wjcc.v9.i11.2419
Table 1 Overall survival rates obtained from research articles comparing therapeutic efficacy between laparoscopy and non-laparoscopy for treatment of hepatocellular carcinoma patients with portal hypertension
Ref.
Country
Number of patients
Proportion of cirrhosis
Causes and their proportion of liver cirrhosis
Diagnostic method of PHT
Proportion of PHT
1-yr overall survival
3-yr overall survival
5-yr overall survival
Statistical significance
Di Sandro et al[42], 2018ItalyLLR/OLR, 75/75AllVirus/Alcohol/Virus + Alcohol/Other, 92/24/16/18Non-invasive testsPartialLLR ≈ OLRLLR/OLR, 98%/90%LLR/OLR, 76%/ 68%LLR/OLR, 60%/58%NSD
Le Roux et al[67], 2017FranceLLR/OLR, 38/24AllVirus/Alcohol/NASH/Other, 6/29/21/6Non-invasive testsPartialLLR ≈ OLRNANANANA
El-Gendi et al[60], 2017EgyptLLR/OLR, 25/25AllVirus, 50Non-invasive testsPartialLLR ≈ OLRNANANANA
Tarantino et al[40], 2017ItalyLLR/OLR, 13/51AllVirus/Alcohol/NASH/Other, 59/1/2/2HVPG + Non-invasive testsPartialLLR ≈ OLRNANANANA
Sposito et al[61], 2016ItalyLLR/OLR, 43/43AllVirus/Other, 67/19Non-invasive testsPartialLLR/OLR, 98%/88%LLR/OLR, 75%/79%LLR/OLR, 38%/46%NSD
Harada et al[43], 2016JapanLLR/OLR, 20/48AllVirus/Other, 58/10Non-invasive testsAllLLR/OLR, 100%/98%LLR/OLR, 90%/68%LLR/OLR, 90%/54%NSD
Memeo et al[48], 2014FranceLLR/OLR, 45/45AllVirus/Alcohol, 64/26Non-invasive testsPartialLLR ≈ OLRLLR/OLR, 88%/63%LLR/OLR, 59%/44%LLR/OLR, 12%/22%NSD
Truant et al[39], 2011FranceLLR/OLR, 36/53AllVirus/Alcohol/Other, 17/55/17HVPG + Non-invasive testsPartialLLR ≈ OLRLLR/OLR, 98%/85%LLR/OLR, 80%/64%LLR/OLR, 70%/46%NSD
Belli et al[44], 2009ItalyLLR/OLR, 54/125AllVirus/Other, 175/4Non-invasive testsPartialLLR ≈ OLRLLR/OLR, 94%/94%LLR/OLR, 67%/62%NANSD
Berger et al[68], 2018AmericaLRFA/ORFA, 478/177AllNANon-invasive testsAllNANANANA
Casaccia et al[50], 2017ItalyLLR/LRFA, 22/24AllVirus/Alcohol/Virus + Alcohol/Other, 33/9/1/2Non-invasive testsPartialLLR/LRFA, 96%/88%LLR/LRFA, 84%/54%LLR/LRFA, 70%/32%SD
Santambrogio et al[69], 2015Italy(LLR+OLR)/LRFA, 76/76AllVirus/Other, 122/30Non-invasive testsPartial(LLR + OLR)/LRFA, 94%/88%(LLR + OLR)/LRFA, 82%/62%(LLR + OLR)/LRFA, 69%/48%SD